Page 2,180«..1020..2,1792,1802,1812,182..2,1902,200..»

Immune cells regulate blood stem cells, research shows

Posted: February 23, 2014 at 7:42 am

Researchers in Bern have discovered that, during a viral infection, immune cells control the blood stem cells in the bone marrow and therefore also the body's own defenses. The findings could allow for new forms of therapy, such as for bone marrow diseases like leukemia.

During a viral infection, the body needs various defense mechanisms -- amongst other things, a large number of white blood cells (leukocytes) must be produced in the bone marrow within a short period of time. In the bone marrow, stem cells are responsible for this task: the blood stem cells. In addition to white blood cells, blood stem cells also produce red blood cells and platelets.

The blood stem cells are located in specialized niches in the bone marrow and are surrounded by specialized niche cells. During an infection, the blood stem cells must complete two tasks: they must first recognise that more blood cells have to be produced and, secondly, they must recognise what kind of.

Now, for the first time, researchers at the Department of Medical Oncology at the University of Bern and Bern University Hospital headed by Prof. Adrian Ochsenbein have investigated how the blood stem cells in the bone marrow are regulated by the immune system's so-called T killer cells during a viral infection. As this regulation mechanism mediated by the immune system also plays an important role in other diseases such as leukemia, these findings could lead to novel therapeutic approaches. The study is being published in the peer-reviewed journal "Cell Stem Cell" today.

T Killer cells trigger defenses

One function of T killer cells is to "patrol" in the blood and remove pathogen-infected cells. However, they also interact with the blood stem cells in the bone marrow. The oncologists in Bern were able to show that messenger substances secreted by the T killer cells modulate the niche cells. In turn, the niche cells control the production and also the differentiation of the blood stem cells.

This mechanism is important in order to fight pathogens such as viruses or bacteria. However, various forms of the bone marrow disease leukemia are caused by a malignant transformation of exactly these blood stem cells. This leads to the formation of so-called leukemia stem cells. In both cases, the mechanisms are similar: the "good" mechanism regulates healthy blood stem cells during an infection, whilst the "bad" one leads to the multiplication of leukemia stem cells. This in turn leads to a progression of the leukemia.

This similarity has already been investigated in a previous project by the same group of researchers. "We hope that this will enable us to better understand and fight infectious diseases as well as bone marrow diseases such as leukemia," says Carsten Riether from the Department of Clinical Research at the University of Bern and the Department of Medical Oncology at Bern University Hospital and the University of Bern.

Story Source:

The above story is based on materials provided by University of Bern. Note: Materials may be edited for content and length.

Read the original:
Immune cells regulate blood stem cells, research shows

Posted in Stem Cell Therapy | Comments Off on Immune cells regulate blood stem cells, research shows

Arthritic knees treated with stem cells by Dr Harry Adelson – 18 months after treatment – Video

Posted: February 22, 2014 at 9:49 pm


Arthritic knees treated with stem cells by Dr Harry Adelson - 18 months after treatment
Linda discusses her outcome of the stem cell treatment she received from Dr Harry Adelson for her arthritic knees.

By: Harry Adelson, N.D.

See the rest here:
Arthritic knees treated with stem cells by Dr Harry Adelson - 18 months after treatment - Video

Posted in Stem Cell Videos | Comments Off on Arthritic knees treated with stem cells by Dr Harry Adelson – 18 months after treatment – Video

Spontaneous Contracting Former Stem Cells – Video

Posted: February 22, 2014 at 9:49 pm


Spontaneous Contracting Former Stem Cells

By: Michelle Sener

Read the rest here:
Spontaneous Contracting Former Stem Cells - Video

Posted in Stem Cell Videos | Comments Off on Spontaneous Contracting Former Stem Cells – Video

Synovium as a source of stem cells for osteoarthritis treatment – Video

Posted: February 22, 2014 at 9:49 pm


Synovium as a source of stem cells for osteoarthritis treatment
http://www.stemcellsarthritistreatment.com What is the best source of stem cells for osteoarthritis treatment? This next item may provide the answer. Sakaguc...

By: Nathan Wei

Here is the original post:
Synovium as a source of stem cells for osteoarthritis treatment - Video

Posted in Stem Cell Videos | Comments Off on Synovium as a source of stem cells for osteoarthritis treatment – Video

Stem Cell Therapy – Studies That Support Regenerative Therapy (Regenexx) – Video

Posted: February 22, 2014 at 9:49 pm


Stem Cell Therapy - Studies That Support Regenerative Therapy (Regenexx)
Dr Robert Wagner of Stem Cell ARTS discusses the research and science behind advanced regenerative medicine therapies and the track record of treating knee, ...

By: StemCell ARTS

See original here:
Stem Cell Therapy - Studies That Support Regenerative Therapy (Regenexx) - Video

Posted in Stem Cell Research | Comments Off on Stem Cell Therapy – Studies That Support Regenerative Therapy (Regenexx) – Video

Duke Health System CEO appointed to head Institute of Medicine – Boston.com

Posted: February 22, 2014 at 4:43 pm

Duke University Health SystemDr. Victor J. Dzau, the current president and CEO of Duke University Health System

Dr. Victor J. Dzau, the current president and CEO of Duke University Health System and chancellor for health affairs at Duke University, has been appointed to a six-year term as the next president of the Institute of Medicine (IOM), effective July 1, 2014. Dr. Dzau will take over the lead role from Dr. Harvey Fineberg, who served in the position for twelve years.

Dr. Dzau began his career in medicine as a cardiologist, having previously taught at Harvard Medical School and served as chair of the department of medicine. He also worked at Brigham and Womens Hospital as the director of research. His ongoing award-winning research has been key in the development of cardiovascular drugs, as well as techniques to repair tissue damage from heart attacks and heart disease using stem cell therapies.

Dr. Eugene Braunwald, often called the father of modern cardiology and a professor of medicine at Harvard Medical School, has known Dr. Dzau for more than 40 years and worked with him at many different stages of his career at Brigham and Womens Hospital and Partners Healthcare. In an interview Wednesday he called the upcoming IOM president a force of nature.

He is what I would call a talented, quadruple threat. A great physician, inspiring teacher, and a very creative scientist, said Dr. Braunwald, who trained Dzau when he was a resident at Brigham and Womens and continued to work with him on cardiovascular research when Dr. Dzau became chief resident, and then faculty at Harvard Medical School. The quadruple threat is that he also sees the larger picture. Hes interested in areas of medicine that most academic physicians have stayed away from. His work and ideas in global and community-based medicine have left an important heritage at each institution where hes worked.

After nearly a decade at Duke, Dr. Dzaus leadership has been credited with the launch of a number of innovative and global-focused medical institutions, including the Duke-National University of Signapore Graduate Medical School, Duke Global Health Institute, Duke Institute for Health Innovation, Duke Cancer Institute, as well as the Duke Translational Medicine Institute.

Im deeply honored to become the next president of the IOM and recognize the critically important role that the IOM will have in improving the health of the nation at a time of extraordinary evolution in biomedical research and health care delivery, Dzau said in a press release from Duke University Health System. The explosion of new data resources, novel technologies and breathtaking research advances make this the most promising time in history for driving innovations that will improve health care delivery, outcomes and quality.

As the health sciences extension of the National Academy of Sciences, the Institute of Medicine is known for its leadership in advancing health sciences and objective medical research nationally as a nonprofit academic research organization. The outgoing IOM president, Dr. Harvey Fineberg (previously Dean of the Harvard School of Public Health) has lead the nonprofit for twelve years. His focus and research have centered around public health policy and an improvement in informed medical decision making.

This leaves the medical community wondering what Dr. Dzau will bring to the Institute.

As a former chairman of the Association of Academic Health Centers (AAHC), Dr. Dzau advocated for the innovative transition of academic medical and health centers into institutions that can survive the rapid transitions in the health care industry. In a recent article in the New England Journal of Medicine, Dr. Dzau discusses the uncertain future of academic medical centers. He argues that industry pressures and cost restraints from the Affordable Care Act limit the research and education-based missions of teaching hospitals.

Read more from the original source:
Duke Health System CEO appointed to head Institute of Medicine - Boston.com

Posted in Cell Medicine | Comments Off on Duke Health System CEO appointed to head Institute of Medicine – Boston.com

Gene Therapy Shows Promise for Treating Heart Attack Victims

Posted: February 22, 2014 at 4:41 pm

Injections of a normally silent gene sparked recovery in pigs induced to have heart attacks

Thinkstock/iStock

When a heart attack brings blood flow to a screeching halt, thats only the first assault on our fist-size organ. Among survivors, the recovery itself fuels more permanent damage to the heart. Scar tissue can harden once-flexible heart muscle, making it less elastic. And as tentacles of this tissue creep over the aorta the heart muscle can no longer fully contract. This long-term damage can minimize the amount of oxygen-rich blood sent throughout the body, which can send patients spiraling into heart failure. Heart transplants are one way to circumvent these scar tissue issues, but donor hearts are always in short supply. Devising other truly effective solutions has long eluded researchers. A form of gene therapy, however, is now showing promise in pigs. It turns out that a normally silent gene called Cyclin A2, or CCNA2, can be coaxed into action to combat the formation of scar tissue in pigs that suffer a heart attack. This treatment sparked regeneration of heart muscle cells in pigs as well as improvements in the volume of blood pushed out with every beat. The finding is published in the February 19 issue of Science Translational Medicine. Gene therapy, the authors hope, may one day join stem cell treatments as a contender for transforming the way doctors treat heart failure. Stem cellbased therapies have already resulted in more healthy tissue and decreased scar mass in human clinical trials as well as small improvements in how much blood the heart can pump from one chamber to another. But as Scientific American reported in April 2013, many questions remain about which stem cells to use and how to prepare them. For this study, researchers randomly assigned 18 pigs recovering from heart attacks to either receive injections of the gene expressed under a promoter (which would force it to be expressed) or the same solution without the gene. Pigs treated with the gene had greater success pushing out blood with each heartbeat, but also produced a greater number of heart muscle cells. These findings echo the teams earlier heart regeneration successes in mice and rats. The researchers replicated their findings in a petri dish and watched adult porcine heart muscle cells treated with the same regimen of gene therapy undergo complete cell division in the dishdemonstrating under a microscope how the heart cells were dividing and thriving with the gene therapy. This new approach mimics the kind of regeneration we see in the newt and zebra fish, says lead author Hina Chaudhry, the director of cardiovascular regenerative medicine at The Mount Sinai Hospital in New York City. If the technique proves successful in humans, it could boost patient recovery rates by helping strengthen heart muscles and improving blood flow, all while giving a needed lift to gene therapy research, which has been slow to gain momentum in the U.S. In 1999 Jesse Gelsinger, 18, died after a gene therapy experiment cost him his life. The virus used to deliver a gene that would potentially control his rare digestive disorder fueled a massive and fatal immune reaction. That highly publicized case, along with other gene therapy missteps, put a pall on the field. Chaudhry says that her team is proceeding with caution and plans to be careful when administering this treatment to patient populations. For patients who have a large heart attack who are at risk of heart failure, I think the therapy is going to be very beneficial, she says. If you have a small heart attack, it probably wont make as much of a difference in overall survival because of advances with todays medicines. As more researchers look to gene therapy for previously intractable human conditions, a success with heart attack treatments could send ripples throughout the field.

2014 Scientific American, a Division of Nature America, Inc.

View Mobile Site All Rights Reserved.

Give a 1 year subscription as low as $14.99

Subscribe Now >>

Go here to see the original:
Gene Therapy Shows Promise for Treating Heart Attack Victims

Posted in Gene therapy | Comments Off on Gene Therapy Shows Promise for Treating Heart Attack Victims

CLINICell Stem Cell Therapy for Knee Meniscus Tear 1 year Follow-Up – Video

Posted: February 22, 2014 at 4:40 pm


CLINICell Stem Cell Therapy for Knee Meniscus Tear 1 year Follow-Up
Stem cell therapy for knee post operative interview. This patient came in with a knee meniscus tear and one year after his initial procedure patient is pain ...

By: ClinicellTech

See the original post here:
CLINICell Stem Cell Therapy for Knee Meniscus Tear 1 year Follow-Up - Video

Posted in Stem Cell Therapy | Comments Off on CLINICell Stem Cell Therapy for Knee Meniscus Tear 1 year Follow-Up – Video

'Largest ever' trial of adult stem cells in heart attack patients begins

Posted: February 22, 2014 at 4:40 pm

Current ratings for: 'Largest ever' trial of adult stem cells in heart attack patients begins

Public / Patient:

5 1 rating

Health Professionals:

3 1 rating

The largest ever trial of adult stem cell therapy in heart attack patients has begun at The London Chest Hospital in the UK.

Heart disease is the world's leading cause of death. Globally, more than 17 million people died from heart disease last year. In the US, over 1 million people suffer a heart attack each year, and about half of them die.

Heart attacks are usually caused by a clot in the coronary artery, which stops the supply of blood and oxygen to the heart. If the blockage is not treated within a few hours, then it causes the heart muscle to die.

The stem cell trial - titled "The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on allcause mortality in acute myocardial infarction," or "BAMI" for short - has been made possible due to a 5.9 million ($8.1 million) award from the European Commission.

The full study involves 19 partners across France, Germany, Italy, Finland, Denmark, Spain, Belgium, Poland, the Czech Republic and the UK.

See the rest here:
'Largest ever' trial of adult stem cells in heart attack patients begins

Posted in Stem Cell Therapy | Comments Off on 'Largest ever' trial of adult stem cells in heart attack patients begins

Fruit Fly Model Organism: How a Developmental Gene Influences Sperm Formation

Posted: February 22, 2014 at 4:40 pm

21.02.2014 - (idw) Ruprecht-Karls-Universitt Heidelberg

Heidelberg researchers have been delving into the basic regulatory mechanisms of stem cell differentiation. Using the Drosophila melanogaster fruit fly as a model organism, the team led by Prof. Dr. Ingrid Lohmann at Heidelberg University's Centre for Organismal Studies was able to show how a special developmental gene from the Hox family influences germline stem cells. These cells are responsible for sperm formation. The scientists found that impairment of Hox gene function resulted in prematurely aged sperms. Press Release Heidelberg, 21 February 2014

Fruit Fly Model Organism: How a Developmental Gene Influences Sperm Formation Heidelberg researchers study basic regulatory mechanisms of stem cell differentiation

Heidelberg researchers have been delving into the basic regulatory mechanisms of stem cell differentiation. Using the Drosophila melanogaster fruit fly as a model organism, the team led by Prof. Dr. Ingrid Lohmann at Heidelberg University's Centre for Organismal Studies was able to show how a special developmental gene from the Hox family influences germline stem cells. These cells are responsible for sperm formation. The scientists, working in the Maintenance and Differentiation of Stem Cells in Development and Disease Collaborative Research Centre (CRC 873), found that impairment of Hox gene function resulted in prematurely aged sperms.

As immature somatic cells, stem cells can mature into different types of cells, thus making them responsible for the development of all the tissues and organs in the body. They are also able to repair damaged adult cells. Advancements in medical research have shown that stem cells can be used to treat certain diseases. To fulfil the promise of stem cell therapy, it is important to discover the function of the respective stem cells and understand how they interact with their environment, that is, the surrounding cells and tissues, explains Prof. Lohmann, who heads the Developmental Biology research group at the Centre for Organismal Studies (COS).

This microenvironment, which stabilises and regulates stem cell activity, is called a stem cell niche. The Heidelberg research team investigated the niches in the testis of the fruit fly. The germline stem cells there produce daughter cells that develop into mature sperms. In our studies, we wanted to find out the nature, if any, of the relationship between germline stem cells and the gene Abd-B, states Prof. Lohmann, who further explains that Abd-B belongs to a family of developmental genes referred to as Hox genes. These Hox genes control the activity of a multitude of other genes that are responsible for the early development of an organism.

In CRC 873, funded by the German Research Foundation, medical and biological scientists investigate the basic regulatory mechanisms that control the self-renewal and differentiation of stem cells. Different model organisms like the fruit fly Drosophila melanogaster are used for their research, aimed at decoding the principles of stem cell control with the aim to also apply them to higher forms of life and eventually humans. The research results of Prof. Lohmann and her team were published in the journal Developmental Cell.

Original publication: F. Papagiannouli, L. Schardt, J. Grajcarek, N. Ha, I. Lohmann: The Hox Gene Abd-B Controls Stem Cell Niche Function in the Drosophila Testis. Developmental Cell, Vol 28. Iss 2, 189-202 (27 January 2014), doi: 10.1016/j.devcel.2013.12.016

Internet information: Research group of Ingrid Lohmann: http://www.cos.uni-heidelberg.de/index.php/i.lohmann?l=_e

Contact: Prof. Dr. Ingrid Lohmann Centre for Organismal Studies Phone: +49 6221 54-51312 ingrid.lohmann@bioquant.uni-heidelberg.de

The rest is here:
Fruit Fly Model Organism: How a Developmental Gene Influences Sperm Formation

Posted in Stem Cell Therapy | Comments Off on Fruit Fly Model Organism: How a Developmental Gene Influences Sperm Formation

Page 2,180«..1020..2,1792,1802,1812,182..2,1902,200..»